Tekturna and the use of Antihypertensives
A Survey of 100 Cardiologists and Primary Care Physicians
Deliverable: Survey with key findings.
Study Description:
|
Topic |
Use of Antihypertensives and the Role of Tekturna |
|
Respondent Type |
Physicians |
|
Specialties Covered |
Primary Care, Internal Medicine, General Practice, Cardiology |
|
Region |
United States Only |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website Duration: 20 minutes Size: 100 respondents Fielding Dates: November 29, 2007 to November 30, 2007 |
Objectives:
To assess the antihypertensives market and, in particular, the use of Tekturna
§ Breakdown of antihypertensive use
§ Duration of treatment
§ Additional versus alternative use of hypertensives
§ Comparison of Angiotensin II receptor antagonists (ARBs)
§ Perception and use of Tekturna
§ Issues that influence the use of Tekturna
§ Impact of generics on predicted future use of ARBs
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
Novartis |
NVS |
Tekturna, Diovan |
|
AstraZeneca |
AZN |
Atacand |
|
Bristol-Myers Squibb/Sanofi Aventis |
BMY/SNY |
Avapro |
|
Daiichi-Sankyo |
DSKYF.PK |
Benicar |
|
Merck |
MRK |
Cozaar |
|
Solvay |
SOLB.BR |
Teveten |
|
Inclusion Criteria |
§ Board-certified or eligible § In practice between 2 and 30 years § More than 70% of time in clinical practice § At least 50 uncomplicated hypertensive patients treated per month |
Print Abstract
For additional information on this study or to purchase, please call:
|
Survey
Cardiology |